Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.

Markman JD, Bolash RB, McAlindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, Roemer FW, Li DJ, Viktrup L, Bramson C, West CR, Verburg KM

Open source

DOI: 10.1097/j.pain.0000000000001928
Published: 2020 Sep 1
Container: Pain
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/j.pain.0000000000001928,
  title = {Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.},
  author = {Markman JD and Bolash RB and McAlindon TE and Kivitz AJ and Pombo-Suarez M and Ohtori S and Roemer FW and Li DJ and Viktrup L and Bramson C and West CR and Verburg KM},
  year = {2020},
  journal = {Pain},
  doi = {10.1097/j.pain.0000000000001928},
  url = {https://doi.org/10.1097/j.pain.0000000000001928}
}

RIS

TY  - JOUR
TI  - Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.
AU  - Markman JD
AU  - Bolash RB
AU  - McAlindon TE
AU  - Kivitz AJ
AU  - Pombo-Suarez M
AU  - Ohtori S
AU  - Roemer FW
AU  - Li DJ
AU  - Viktrup L
AU  - Bramson C
AU  - West CR
AU  - Verburg KM
PY  - 2020
JO  - Pain
DO  - 10.1097/j.pain.0000000000001928
UR  - https://doi.org/10.1097/j.pain.0000000000001928
ER  -

APA

JD, M., RB, B., TE, M., AJ, K., M, P., S, O., FW, R., DJ, L., L, V., C, B., CR, W., & KM, V. (2020). Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.. Pain. https://doi.org/10.1097/j.pain.0000000000001928

Source records

pubmed · retrieved 2026-09-27T00:25:03.271Z